Marker Systems Based on MicroRNA Gene Methylation for the Diagnosis of Stage I-II Breast Cancer
- Autores: Braga E.1,2, Filippova E.1, Loginov V.1,2, Pronina I.1, Burdennyi A.1, Kazubskaya T.3, Fridman M.4, Khodyrev D.5, Kushlinskii N.3
-
Afiliações:
- Research Institute of General Pathology and Pathophysiology
- Medical Genetic Research Center
- N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
- N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences
- Federal Research Clinical Center of Specialized Types of Medical Care and Medical Technologies, Federal Biomedical Agency of Russia
- Edição: Volume 168, Nº 2 (2019)
- Páginas: 280-284
- Seção: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/242404
- DOI: https://doi.org/10.1007/s10517-019-04691-x
- ID: 242404
Citar
Resumo
Groups of microRNA genes, methylation of which is associated with the initial (I-II) stages of breast cancer, are determined, and new markers and marker systems for the disease diagnosis were created on the basis of these data. A total of 14 genes in which methylation was associated with breast cancer were identified with the use of methyl-specific PCR on a representative sample of 70 tumor specimens. Analysis of 46 specimens from patients with clinical stages I and II detected 9 genes (MIR-124-1, MIR-124-3, MIR-125b-1, MIR-129-2, MIR-132, MIR-148a, MIR-193a, MIR-34b/c, and MIR-9-3), in which methylation was associated with the initial stages of the disease. Using ROC analysis, we formed two systems including 6 markers each and detecting breast cancer at stages I-II with high sensitivity (89 and 91%) and specificity (88%) at AUC=0.92-0.93. These sets were validated on the total sample of 70 specimens including all disease stages; they showed 93 and 94% sensitivities, 88% specificity, and AUC=0.95. Highly sensitive systems of markers, based on microRNA gene methylation, were created for the diagnosis of breast cancer at stages I-II.
Sobre autores
E. Braga
Research Institute of General Pathology and Pathophysiology; Medical Genetic Research Center
Autor responsável pela correspondência
Email: eleonora10_45@mail.ru
Rússia, Moscow; Moscow
E. Filippova
Research Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Rússia, Moscow
V. Loginov
Research Institute of General Pathology and Pathophysiology; Medical Genetic Research Center
Email: eleonora10_45@mail.ru
Rússia, Moscow; Moscow
I. Pronina
Research Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Rússia, Moscow
A. Burdennyi
Research Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
Rússia, Moscow
T. Kazubskaya
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Rússia, Moscow
M. Fridman
N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences
Email: eleonora10_45@mail.ru
Rússia, Moscow
D. Khodyrev
Federal Research Clinical Center of Specialized Types of Medical Care and Medical Technologies, Federal Biomedical Agency of Russia
Email: eleonora10_45@mail.ru
Rússia, Moscow
N. Kushlinskii
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
Rússia, Moscow